logo
logo

Primmune Therapeutics Announces Close of Series A Financing

Primmune Therapeutics Announces Close of Series A Financing

01/12/21, 1:10 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan diego
Round Type
series a
Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise to $31.4 million. These funds will be used to support the development of PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonist as a therapeutic-adjuvant for acute viral diseases and cancer.

Company Info

Company
Primmune Therapeutics
Location
san diego, california, united states
Additional Info
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases. For more information, please visit: www.primmunerx.com.